抗血管生成药物的研究现状及心血管不良反应
The Research Status and Cardiovascular Ad-verse Reactions of Antiangiogenic Drugs
DOI: 10.12677/ACM.2023.13102302, PDF,  被引量   
作者: 胡丽婷, 赵紫薇:西安医学院研究生工作部,陕西 西安;姜 馨*:陕西省人民医院心血管内科,陕西 西安
关键词: 血管内皮生长因子心血管疾病癌症高血压Vascular Endothelial Growth Factor Cardiovascular Disease Cancer Hypertension
摘要: 抗血管生成药物在抗癌治疗中占有至关重要的地位,其通过抑制内皮细胞中的血管内皮生长因子信号转导通路阻止肿瘤血管生长和分化,使癌细胞无法获取营养从而达到抑制肿瘤的目的。然而,随着此类药物在抗癌治疗中的广泛应用,产生了一系列不良反应,其中最重要的为心血管不良反应,包括高血压、冠状动脉疾病、心律失常、心力衰竭、外周动脉疾病、瓣膜病和心包疾病等。不良反应发生率主要取决于药物类型、药物剂量、恶性肿瘤类型、心血管基础疾病和伴随疗法。
Abstract: Antiangiogenic drugs play a crucial role in the treatment of cancer by inhibiting vascular endotheli-al growth factor signal transduction pathways in endothelial cells and preventing tumor vessel growth and differentiation. So cancer cells cannot access nutrients to achieve the goal of tumor sup-pression. However, with the wide application of these drugs in anti-cancer therapy, a series of ad-verse reactions have occurred. The most important is cardiovascular disease, including hyperten-sion, coronary artery disease, arrhythmias, heart failure, peripheral artery disease, valvular disease and pericardial disease. The incidence of the adverse reactions mainly depends on the type of drug, dosage, the type of cancer, cardiovascular diseases and concomitant therapy.
文章引用:胡丽婷, 赵紫薇, 姜馨. 抗血管生成药物的研究现状及心血管不良反应[J]. 临床医学进展, 2023, 13(10): 16440-16445. https://doi.org/10.12677/ACM.2023.13102302

参考文献

[1] Siegel, R.L., Miller, K.D., Wagle, N.S., et al. (2023) Cancer Statistics, 2023. CA: A Cancer Journal for Clinicians, 73, 17-48. [Google Scholar] [CrossRef] [PubMed]
[2] Oeffinger, K.C., Mertens, A.C., Sklar, C.A., et al. (2006) Chronic Health Conditions in Adult Survivors of Childhood Cancer. The New England Journal of Medicine, 355, 1572-1582. [Google Scholar] [CrossRef
[3] Chen, D.Y., Liu, J.R., Tseng, C.N., et al. (2022) Major Adverse Car-diovascular Events in Patients with Renal Cell Carcinoma Treated with Targeted Therapies. JACC: CardioOncology, 4, 223-234. [Google Scholar] [CrossRef] [PubMed]
[4] Wang, Y., Cui, C., Ren, X., et al. (2022) Cardiovascular Toxicity Associated with Angiogenesis Inhibitors: A Comprehensive Pharmacovigilance Analysis Based on the FDA Adverse Event Reporting System Database from 2014 to 2021. Frontiers in Cardiovascular Medicine, 9, Article 988013. [Google Scholar] [CrossRef] [PubMed]
[5] Lenihan, D.J., Cardinale, D. and Cipolla, C.M. (2010) The Com-pelling Need for a Cardiology and Oncology Partnership and the Birth of the International CardiOncology Society. Pro-gress in Cardiovascular Diseases, 53, 88-93. [Google Scholar] [CrossRef] [PubMed]
[6] Schlumberger, M., Tahara, M., Wirth, L.J., et al. (2015) Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer. The New England Journal of Medicine, 372, 621-630. [Google Scholar] [CrossRef
[7] Hoeben, A., Landuyt, B., Highley, M.S., et al. (2004) Vascular En-dothelial Growth Factor and Angiogenesis. Pharmacological Reviews, 56, 549-580. [Google Scholar] [CrossRef] [PubMed]
[8] Folkman, J. (2002) Role of Angiogenesis in Tumor Growth and Metastasis. Seminars in Oncology, 29, 15-18. [Google Scholar] [CrossRef
[9] Vimalraj, S. (2022) A Concise Review of VEGF, PDGF, FGF, Notch, Angiopoietin, and HGF Signalling in Tumor Angiogenesis with a Focus on Alternative Approaches and Future Directions. International Journal of Biological Macromolecules, 221, 1428-1438. [Google Scholar] [CrossRef] [PubMed]
[10] Hicklin, D.J. and Ellis, L.M. (2005) Role of the Vascular En-dothelial Growth Factor Pathway in Tumor Growth and Angiogenesis. Journal of Clinical Oncology, 23, 1011-1027. [Google Scholar] [CrossRef
[11] Jang, H.J., Kim, B.J., Kim, J.H. and Kim, H.S. (2017) The Addition of Bevacizumab in the First-Line Treatment for Metastatic Colorectal Cancer: An Updated Meta-Analysis of Randomized Trials. Oncotarget, 8, 73009-73016. [Google Scholar] [CrossRef] [PubMed]
[12] Li, Y., Wang, W., Gao, R., Xu, X.M. and Zhang, Y. (2021) Ge-nome-Wide Prioritization Reveals Novel Gene Signatures Associated with Cardiotoxic Effects of Tyrosine Kinase Inhib-itors. Oncology Letters, 21, Article No. 94. [Google Scholar] [CrossRef] [PubMed]
[13] Du, Z. and Lovly, C.M. (2018) Mechanisms of Receptor Tyrosine Ki-nase Activation in Cancer. Molecular Cancer, 17, Article No. 58. [Google Scholar] [CrossRef] [PubMed]
[14] Chaar, M., Kamta, J. and Ait-Oudhia, S. (2018) Mechanisms, Monitoring, and Management of Tyrosine Kinase Inhibitors-Associated Cardiovascular Toxicities. OncoTargets and Therapy, 11, 6227-6237. [Google Scholar] [CrossRef
[15] Force, T., Krause, D.S. and Van Etten, R.A. (2007) Molecular Mecha-nisms of Cardiotoxicity of Tyrosine Kinase Inhibition. Nature Reviews Cancer, 7, 332-344. [Google Scholar] [CrossRef] [PubMed]
[16] Zamorano, J.L., Lancellotti, P., Rodriguez Muñoz, D., et al. (2016) 2016 ESC Position Paper on Cancer Treatments and Cardiovascular Toxicity Developed under the Auspices of the ESC Committee for Practice Guidelines: The Task Force for Cancer Treatments and Cardiovascular Toxicity of the European Society of Cardiology (ESC). European Heart Journal, 37, 2768-2801. [Google Scholar] [CrossRef] [PubMed]
[17] Kamba, T. and Mcdonald, D.M. (2007) Mechanisms of Adverse Effects of Anti-VEGF Therapy for Cancer. British Journal of Cancer, 96, 1788-1795. [Google Scholar] [CrossRef] [PubMed]
[18] Zhao, T., Wang, X., Xu, T., Xu, X.D. and Liu, Z.H. (2017) Bevacizumab Significantly Increases the Risks of Hypertension and Proteinuria in Cancer Patients: A Sys-tematic Review and Comprehensive Meta-Analysis. Oncotarget, 8, 51492-51506. [Google Scholar] [CrossRef] [PubMed]
[19] Hamnvik, O.P., Choueiri, T.K., Turchin, A., et al. (2015) Clinical Risk Factors for the Development of Hypertension in Patients Treated with Inhibitors of the VEGF Signaling Pathway. Cancer, 121, 311-319. [Google Scholar] [CrossRef] [PubMed]
[20] Totzeck, M., Mincu, R.I. and Rassaf, T. (2017) Cardiovascular Adverse Events in Patients with Cancer Treated with Bevacizumab: A Meta-Analysis of More than 20 000 Patients. Journal of the American Heart Association, 6, e006278. [Google Scholar] [CrossRef
[21] Haroon, Z.A., Amin, K., Saito, W., et al. (2002) SU5416 Delays Wound Healing through Inhibition of TGF-β 1 Activation. Cancer Biology & Therapy, 1, 121-126. [Google Scholar] [CrossRef] [PubMed]
[22] Richards, C.J., Je, Y., Schutz, F.A., et al. (2011) Incidence and Risk of Conges-tive Heart Failure in Patients with Renal and Nonrenal Cell Carcinoma Treated with Sunitinib. Journal of Clinical Oncol-ogy, 29, 3450-3456. [Google Scholar] [CrossRef
[23] Chintalgattu, V., Ai, D., Langley, R.R., et al. (2010) Cardiomyo-cyte PDGFR-β Signaling Is an Essential Component of the Mouse Cardiac Response to Load-Induced Stress. The Jour-nal of Clinical Investigation, 120, 472-484. [Google Scholar] [CrossRef
[24] Vallerio, P., Orenti, A., Tosi, F., et al. (2022) Major Adverse Cardiovascu-lar Events Associated with VEGF-Targeted Anticancer Tyrosine Kinase Inhibitors: A Real-Life Study and Proposed Al-gorithm for Proactive Management. ESMO Open, 7, Article ID: 100338. [Google Scholar] [CrossRef] [PubMed]